Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

Seck, Thomas; Nauck, Michael A.; Sheng, D.; Sunga, S.; Davies, Michael J.; Stein, Peter; Kaufman, Keith D.; Amatruda, John M.

doi:10.1111/j.1742-1241.2010.02353.x

Cited by 193 publications

(154 citation statements)

References 22 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…1). In the two longest-running trials, the 'escape phenomenon', assessed by a secondary increase in HbA 1c levels between weeks 24 and 104 following a good initial HbA 1c reduction, was significantly less pronounced with sitagliptin 100 mg or vildagliptin 100 mg than with glipizide or glimepiride, respectively [28,31], suggesting better β-cell protection and durability of glucose control with a DPP-4 inhibitor.…”

Section: Gliptins Combined With Metforminmentioning

confidence: 99%

“…However, in the present review, only head-to-head trials vs active comparators are presented in brief. Gliptins have also been compared with SUs (glimepiride, glipizide, gliclazide) [27][28][29][30][31][32][33][34], TZDs (pioglitazone 30 mg, rosiglitazone 8 mg) [35][36][37][38][39] and GLP-1 receptor agonists (exenatide, liraglutide) [36,40,41]. However, only one head-to-head study compared two different DPP-4 inhibitors in the same trial: saxagliptin 5 mg with sitaglitptin 100 mg as add-ons to basal metformin therapy [42].…”

Section: Gliptins Combined With Metforminmentioning

confidence: 99%

See 1 more Smart Citation

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Scheen¹

2012

Diabetes & Metabolism

176

124

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA 1c reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thiazolidinedione (TZD; with the advantage of no weight gain). In metformin-treated patients, gliptins were associated with similar HbA 1c reductions compared with a sulphonylurea (SU; with the advantage of no weight gain, considerably fewer hypoglycaemic episodes and no need for titration) and a TZD (with the advantage of no weight gain and better overall tolerability). DPP-4 inhibitors also exert clinically relevant glucose-lowering effects compared with a placebo in patients treated with SU or TZD (of potential interest when metformin is either not tolerated or contraindicated), and as oral triple therapy with a good tolerability profile when added to a metformin-SU or pioglitazone-SU combination. Several clinical trials also showed a consistent reduction in HbA 1c when DPP-4 inhibitors were added to basal insulin therapy, with no increased risk of hypoglycaemia. Because of the complex pathophysiology of type 2 diabetes and the complementary actions of glucose-lowering agents, initial combination of a DPP-4 inhibitor with either metformin or a glitazone may be applied in drug-naive patients, resulting in greater efficacy and similar safety compared with either drug as monotherapy. However, DPP-4 inhibitors were less effective than GLP-1 receptor agonists for reducing HbA 1c and body weight, but offer the advantage of being easier to use (oral instead of injected administration) and lower in cost. Only one head-tohead trial demonstrated the non-inferiority of saxagliptin vs sitagliptin. Clearly, more trials of direct comparisons between different incretin-based therapies are needed. Because of their pharmacokinetic characteristics, pharmacodynamic properties (glucose-dependent glucose-lowering effect) and good overall tolerability profile, DPP-4 inhibitors may have a key role to play in patients with renal impairment and in the elderly. The role of DPP-4 inhibitors in the therapeutic armamentarium of type 2 diabetes is rapidly evolving as their potential strengths and weaknesses become better defined mainly through controlled clinical trials. Keywords:Clinical trial-DPP-4 inhibitor; Alogliptin; Linagliptin; Saxagliptin; Sitagliptin; Vildagliptin; Type 2 diabetes mellitus; Review Résumé Les inhibiteurs de la DPP-4 dans le traitement du diabète de type 2 : revue critique des essais cliniques contrôlés.Les inhibiteurs de la dipeptidylpeptidase-4 (DPP-4) offrent de nouvelles options pour le traitement du diabète de type 2. Des comparaisons directes avec d'autres médicaments antidiabétiques chez des patients naïfs de tout traitement ont démontré que les inhibiteurs de la DPP-4 étaient un peu moins puissants pour diminuer ...

show abstract

Section: Gliptins Combined With Metforminmentioning

confidence: 99%

Section: Gliptins Combined With Metforminmentioning

confidence: 99%

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Scheen¹

2012

Diabetes & Metabolism

176

124

View full text Add to dashboard Cite

show abstract

“…However, the evidence supporting this proposed benefit is limited. 46 In fact, a recent randomized controlled trial 46 suggested that dipeptidyl peptidase-4 inhibitors do not confer benefits in terms of sustained glycemic control. Nevertheless, if future long-term studies demonstrate differences in glycemic durability between agents over time, or in other clinically important outcomes, cost-effectiveness estimates will have to be updated.…”

Section: Limitationsmentioning

confidence: 99%

Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

Klarenbach¹,

Cameron²,

Singh³

et al. 2011

Canadian Medical Association Journal

View full text Add to dashboard Cite

“…Yanai et al [3] had found a significant and negative correlation between change in body Another study performed by Seck et al [4] result was for the PP cohort, Relative to baseline, sitagliptin was associated with significant weight loss (p<0.05) (-1.6 kg) compared with weight gain (+0.7 kg) with glipizide. Study conducted by Yang et al [5] in 2012 revealed a small decrease from baseline body weight in the placebo group compared with no change in the sitagliptin group (between-group difference 0.5kg; p<0.01).…”

Section: Methodsmentioning

confidence: 96%

A Croos Sectional Study in North Eastern Uttar Pradesh Population for the Estimation of Hdl, Triglycerides Levels in Recently Diagnosed Patients With Diabetes Mellitus Type 2 Taking Metformin Alone, Metformin With Add on Sitagliptin and Sitagliptin Alone

Neerjesh¹

2017

WJPR

View full text Add to dashboard Cite

show abstract

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

Cited by 193 publications

References 22 publications

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

A Croos Sectional Study in North Eastern Uttar Pradesh Population for the Estimation of Hdl, Triglycerides Levels in Recently Diagnosed Patients With Diabetes Mellitus Type 2 Taking Metformin Alone, Metformin With Add on Sitagliptin and Sitagliptin Alone

Contact Info

Product

Resources

About